Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04752696 · ClinicalTrials.gov registry record · Phase 2
Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 2 study, sponsored by Cardiff Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT04752696 is a Phase 2 study that has completed, run by Cardiff Oncology. The registered enrollment target is 41 participants.
The verdict
NCT04752696, a Phase 2 study, has completed, sponsored by Cardiff Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The main objective of this trial is to assess the efficacy of onvansertib in combination with nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed metastatic pancreatic ductal adenocarcinoma (PDAC).
Interventions
- DRUG Fluorouracil
- DRUG Leucovorin
- DRUG Nanoliposomal irinotecan
- DRUG Onvansertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2021-05-25 |
| Est. Completion | 2024-12-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04752696
The ClinicalTrials.gov registry entry for NCT04752696 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cardiff Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fluorouracil is the first listed.
NCT04752696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04752696 about?
NCT04752696 is a clinical study titled "Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma". The main objective of this trial is to assess the efficacy of onvansertib in combination with nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed metastatic pancreatic ductal adenocarcinoma (PDAC).
What is the current status of trial NCT04752696?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2021-05-25. Estimated completion is 2024-12-24.
What interventions are being tested in trial NCT04752696?
The interventions under investigation include: Fluorouracil (DRUG), Leucovorin (DRUG), Nanoliposomal irinotecan (DRUG), Onvansertib (DRUG).
Who is sponsoring clinical trial NCT04752696?
This trial is sponsored by Cardiff Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.